Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | GSK3A | P49840 | 3/20 | 0.52 |
| ▸ | RPS6KA3 | P51812 | 3/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.52 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.49 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.49 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.49 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.49 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.49 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.49 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.49 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.49 |
| ▸ | TYMP | P19971 | 4/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9658521 | 0.93 | ALDH1A1 (0.54) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL10001659 | 0.91 | LMNA (0.64) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL14943053 | 0.91 | LMNA (0.64) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL10017765 | 0.91 | LMNA (0.64) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL3150082 | 0.91 | LMNA (0.64) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL24191242 | 0.91 | LMNA (0.64) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL10048818 | 0.91 | LMNA (0.64) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL20857280 | 0.87 | ALDH1A1 (0.54) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL9300768 | 0.84 | PRKAB2 (0.56) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL5455528 | 0.84 | PRKAB2 (0.56) | ALDH1A1LMNATP53MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007587-A1 | DERIVATIVES OF MENTHOL AND USES THEREOF | FONA TECH LLC (US) | 2026-01-08 | — | — | US | disclosed |
| EP-4038048-B1 | DERIVATIVES OF MENTHOL AND USES THEREOF | FONA TECH LLC (US) | 2025-11-05 | — | — | EP | disclosed |
| US-20240074958-A1 | DERIVATIVES OF MENTHOL AND USES THEREOF | FONA TECHNOLOGIES, LLC | 2024-03-07 | — | — | US | disclosed |
| EP-4038048-A1 | DERIVATIVES OF MENTHOL AND USES THEREOF | Board of Trustees of Northern Illinois University (US) | 2022-08-10 | — | — | EP | disclosed |
| US-20030204080-A1 | Methods for producing nucleoside derivatives and intermediates therefor | AJINOMOTO CO. INC (JP) | 2003-10-30 | — | — | US | disclosed |
| US-20030004330-A1 | Methods for producing nucleoside derivatives and intermediates therefor | AJINOMOTO CO. INC (JP) | 2003-01-02 | — | — | US | disclosed |
| US-6500946-B1 | LOW COST, SIMPLE, HIGH YIELD PRODUCTION, INCLUDING THAT OF ANTIVIRAL AGENT 9-(2,3-DIDEOXY-2-FLUORO-.BETA.-D-THREO-PENTOFURANOSYL)ADENINE (FDDA) | AJINOMOTO CO., INC. (JP) | 2002-12-31 | — | — | US | disclosed |
| US-6090937-A | Methods for producing nucleoside derivatives and intermediates therefor | AJINOMOTO CO., INC. (JP) | 2000-07-18 | — | — | US | disclosed |
| EP-0945460-A1 | Methods for producing nucleoside derivatives and intermediates therefore | Ajinomoto Co., Inc. (JP) | 1999-09-29 | — | — | EP | disclosed |
| US-5106962-A | Reacting nucleosides with viologens in the presence of base | AJINOMOTO CO., INC. (JP) | 1992-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004330-A1 | Methods for producing nucleoside derivatives and intermediates therefor | DCTD, ADAR, IMPDH1 | ALDH1A1 965/4885LMNA 2833/4885TP53 3026/4885 |
| US-20240074958-A1 | DERIVATIVES OF MENTHOL AND USES THEREOF | GNMT, GPR18, MGAT3 | ALDH1A1 2173/4885LMNA 1908/4885TP53 3298/4885 |
| US-20030204080-A1 | Methods for producing nucleoside derivatives and intermediates therefor | DCTD, ADAR, IMPDH1 | ALDH1A1 965/4885LMNA 2833/4885TP53 3026/4885 |
| US-20260007587-A1 | DERIVATIVES OF MENTHOL AND USES THEREOF | MGAT2, MGAT1, MGAT3 | ALDH1A1 3092/4885LMNA 2444/4885TP53 2809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.